Altogether, the preclinical and clinical data on OEC suggest that selective targeting of ERβ may provide a significant improvement of existing therapy for the treatment of ovarian cancer, at least for the patient population that expresses ERβ. This evidence concerns the gene ESR2 and ovarian carcinoma.